

Supplementary Material

Article Title: Measuring What Matters: Further Validation for the Tardive Dyskinesia Impact Scale, a Novel Patient-Reported Outcome Measure in Valbenazine Clinical Trials

Authors: Morgan Bron, PharmD, MS; Susan D. Mathias, MPH; Donald E. Stull, PhD; Hui Zhang, PhD; Michelle Turner, MS; Eduardo Dunayevich, MD; Ashok Parameswaran, MD; Dawn Vanderhoef, PhD, DNP, PMHNP-BC, FAANP; M. Mercedes Perez-Rodriguez, MD, PhD; Christoph U. Correll, MD

DOI Number: 10.4088/JCP.25nr16047


LIST OF SUPPLEMENTARY MATERIAL FOR THE ARTICLE

1. [Figure 1](#) Change in TDIS Item Mean Scores From Baseline to Week 48 for Individuals Receiving Valbenazine (n=181)

DISCLAIMER

This Supplementary Material has been provided by the authors as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary Figure 1. Change in TDIS item mean scores from baseline to week 48 for individuals receiving valbenzazine (n=181)



Abbreviations: TDIS: Tardive Dyskinesia Impact Scale.